Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure disorders.
### Primary Indications
Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS). Off-label uses include other epilepsy syndromes and anxiety disorders.
### Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):** Start at 5 mg twice daily. Titrate by 5-10 mg per day every week as needed, up to a maximum of 20 mg twice daily.
* **Other Seizure Disorders (Off-label):** Dosing is highly variable and dependent on individual response and concomitant antiepileptic drugs. Typical starting doses may range from 5 mg to 10 mg once or twice daily, with gradual titration to a maximum of 20 mg twice daily.
### Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* **2 to less than 10 years:** Start at 2.5 mg twice daily. Titrate by 2.5-5 mg per day every week as needed, up to a maximum of 10 mg twice daily.
* **10 years and older (or adult weight):** Start at 5 mg twice daily. Titrate by 5-10 mg per day every week as needed, up to a maximum of 20 mg twice daily.
* **Other Seizure Disorders (Off-label):** Dosing is highly variable and dependent on age, weight, and concomitant antiepileptic drugs. Local protocols should be consulted.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment is recommended, but lower doses and slower titration may be necessary.
* **Renal Impairment:** Use with caution. No specific dose adjustment is recommended, but lower doses and slower titration may be necessary.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
### Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, respiratory tract infection, irritability, aggression, lethargy, ataxia, vomiting.
* **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal, paradoxical reactions.
### Key Drug Interactions
* **CNS Depressants (alcohol, opioids, other benzodiazepines, sedating antihistamines):** Additive CNS depression.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam levels and efficacy.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, macrolide antibiotics):** May increase clobazam levels and risk of toxicity.
* **Valproic Acid:** Increased valproic acid levels have been reported, potentially increasing the risk of valproic acid toxicity. Monitor valproic acid levels and for signs of toxicity.
### Monitoring
* Monitor for clinical effectiveness (seizure frequency).
* Monitor for signs and symptoms of suicidal behavior or ideation.
* Monitor for excessive sedation, ataxia, and cognitive impairment.
* Monitor for signs of withdrawal upon discontinuation.
* Consider monitoring for drug interactions, especially with concomitant medications affecting CYP3A4 or CNS depressants.
### Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Withdrawal symptoms can occur upon abrupt discontinuation; taper gradually.
* Risk of serious skin reactions is significant; educate patients on early signs and symptoms.
* Due to its long half-life, accumulation can occur, especially in elderly patients or those with hepatic/renal impairment.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local institutional protocols before making any clinical decisions.*
